Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year.....
+See More2020-03-05 08:28:00 Thursday ET
The Stanford computer science overlords Larry Page and Sergey Brin design and develop Google as an Internet search company. Janet Lowe (2009) Google s
2027-04-30 12:31:00 Friday ET
In recent years, the current AI-driven stock market rally may or may not turn out to be another major asset bubble in global human history. For the pract
2022-09-15 11:38:00 Thursday ET
Capital structure choices for private firms The Kauffman Firm Survey (KFS) database provides comprehensive panel data on 5,000+ American private firms fr
2027-07-31 13:25:00 Saturday ET
In the broader context of stablecoins for asset tokenization worldwide, many governments now seek to enter the global markets for stablecoins and other U.S.
2018-03-15 07:41:00 Thursday ET
The Trump administration's $1.5 trillion hefty tax cuts and $1 trillion infrastructure expenditures may speed up the Federal Reserve interest rate hike
2019-10-15 09:13:00 Tuesday ET
U.K. prime minister Boris Johnson encounters defeat during his new premiership. The first major vote would pave the path of least resistance to passing a no